Search results
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 1 day agoIn ACE-Breast-02, ARX788 managed to prolong progression-free survival (PFS) compared to LC, with...
Placing COVID patients in skilled nursing facilities led to increased cases, deaths, study finds
Center for Infectious Disease Research and Policy· 9 hours agoOutcomes were assessed during a 15-week follow-up period. The authors found that exposed SNFs had a...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both...
Valley City Times Record· 1 day agoJohnson & Johnson today announced data from the Phase 3 PERSEUS study showing deepening of responses...
Infarct size does not affect treatment effect of early versus late direct oral anticoagulant...
Medical Xpress· 7 days agoFor individuals with minor, moderate, or major stroke, the treatment effect of early versus late...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoThese safety results are in keeping with the known toxicities of Enhertu and Perjeta....
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 1 day agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Exploring high-quality microbial genomes by assembling short-reads with long-range connectivity -...
Nature· 5 days agoHere, the authors develop Pangaea, an assembler that uses short-reads with long-range connectivity to create high-quality microbial genomes affordably, showing it outperforms existing methods ...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following...
Digital Journal· 2 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, presented updated clinical ...
Early use of antivirals linked to reduced risk of long COVID
Center for Infectious Disease Research and Policy· 1 day agoOverall early oral antiviral drugs reduced long-COVID risk 23% (risk ratio [RR] 0.77; 95% confidence...
Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib...
Valley City Times Record· 1 day agoJohnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced ...